News Focus
News Focus
Followers 236
Posts 10817
Boards Moderated 0
Alias Born 07/17/2006

Re: venus537 post# 269237

Sunday, 04/26/2020 7:56:21 AM

Sunday, April 26, 2020 7:56:21 AM

Post# of 448089
venus537....

Quote: "Publicly Amarin's plan is then to compete with the generics with their own generic Vascepa in the U.S. and have partnerships in Europe. That sounds like a nightmare within a nightmare."

Why so? The perfect is the enemy of the good. The market for Vascepa is going to be mind blowing...A fraction of Vascepa sales could be worth more than the whole pie of another drug...Amarin is going to have tied up a lot of the suppliers and very likely could have lower costs in producing the drug to the point where it is no longer profitable for the generics..I have always and still believe Vascepa will pretty much sell itself..Most people want to live longer..You can not look at the first couple of months of sales particularly when we are under quarantine.
Do we really need a partner in Europe...How bout using the Japanese model.Don't partner..Just open the dealerships employ the locals,,and have your people in charge of management..

The generics are not home yet..There is the very sticky subject of the fact Vascepa embodies a patented capsule which tends to retard the degradation of the EPA...Getting around those patents and complying with FDA requirements might lead to a couple of years or more delay or maybe the Generics will not get Judge Du in the next patent fight..

Keep your sunny side up...Pleasant dreams...

":>) JL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News